Key Takeaways
- • Veritas Aortic Solutions closed a $12 million seed funding round led by experienced MedTech angel investors, with significant participation from Cedars-Sinai Intellectual Property Company and inQB8's existing investor base.
- • The company is advancing the Veritas Transcatheter Valved Aortic Root Conduit (TVARC), a non-surgical, interventional treatment designed for high-risk root and ascending aortic diseases including dissections, aneurysms, and other pathologies affecting the aortic root, coronary ostia, and ascending aorta.
- • Veritas Aortic Solutions is the latest spin-out from inQB8 Medical Technologies, headquartered in Costa Mesa, California, indicating continued activity in the inQB8 portfolio's commercialization strategy.
- • Funding will support continued development of the TVARC technology through First-in-Human clinical use, representing a critical inflection point in the device's clinical validation pathway.
Summary
Veritas Aortic Solutions, a newly spun-out venture from inQB8 Medical Technologies, has secured $12 million in seed-stage financing to advance its lead therapeutic asset, the Veritas Transcatheter Valved Aortic Root Conduit (TVARC). The funding round demonstrates investor confidence in innovative approaches to aortic root and ascending aortic disease management, a therapeutic area with significant clinical and market opportunity among high-risk patient populations.
The financing was led by a syndicate of experienced MedTech angel investors alongside Cedars-Sinai Intellectual Property Company, which participated substantially in the round. inQB8's existing investor base also supported the financing, reflecting continuity of capital from the parent platform. This investor composition—combining angel-stage MedTech expertise with an academic medical center's IP arm—suggests validation from both commercial and clinical stakeholders familiar with early-stage medical device development.
The capital will fund continued development of the TVARC platform and support the company's progression toward First-in-Human clinical use. The TVARC is positioned as a comprehensive, minimally invasive interventional solution targeting high-risk patients with root and ascending aortic pathologies, including aortic dissections, aneurysms, and conditions affecting the aortic root, coronary ostia, and ascending aorta segments. This positioning addresses a clinical gap where existing therapeutic options may be limited for high-risk surgical candidates.
Veritas Aortic Solutions' emergence as a separate entity from inQB8 Medical Technologies underscores the parent organization's strategy of identifying differentiated technologies within its portfolio and establishing independent operating companies to pursue focused clinical and commercial objectives.
The financing was led by a syndicate of experienced MedTech angel investors alongside Cedars-Sinai Intellectual Property Company, which participated substantially in the round. inQB8's existing investor base also supported the financing, reflecting continuity of capital from the parent platform. This investor composition—combining angel-stage MedTech expertise with an academic medical center's IP arm—suggests validation from both commercial and clinical stakeholders familiar with early-stage medical device development.
The capital will fund continued development of the TVARC platform and support the company's progression toward First-in-Human clinical use. The TVARC is positioned as a comprehensive, minimally invasive interventional solution targeting high-risk patients with root and ascending aortic pathologies, including aortic dissections, aneurysms, and conditions affecting the aortic root, coronary ostia, and ascending aorta segments. This positioning addresses a clinical gap where existing therapeutic options may be limited for high-risk surgical candidates.
Veritas Aortic Solutions' emergence as a separate entity from inQB8 Medical Technologies underscores the parent organization's strategy of identifying differentiated technologies within its portfolio and establishing independent operating companies to pursue focused clinical and commercial objectives.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.